RU2752880C2 - Химерный антигенный рецептор - Google Patents

Химерный антигенный рецептор Download PDF

Info

Publication number
RU2752880C2
RU2752880C2 RU2017132978A RU2017132978A RU2752880C2 RU 2752880 C2 RU2752880 C2 RU 2752880C2 RU 2017132978 A RU2017132978 A RU 2017132978A RU 2017132978 A RU2017132978 A RU 2017132978A RU 2752880 C2 RU2752880 C2 RU 2752880C2
Authority
RU
Russia
Prior art keywords
car
leu
glu
gly
endodomain
Prior art date
Application number
RU2017132978A
Other languages
English (en)
Russian (ru)
Other versions
RU2017132978A3 (cg-RX-API-DMAC7.html
RU2017132978A (ru
Inventor
Мартен ПЮЛЕ
Шон КОРДОБА
Original Assignee
Отолус Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Отолус Лимитед filed Critical Отолус Лимитед
Publication of RU2017132978A publication Critical patent/RU2017132978A/ru
Publication of RU2017132978A3 publication Critical patent/RU2017132978A3/ru
Application granted granted Critical
Publication of RU2752880C2 publication Critical patent/RU2752880C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2017132978A 2015-03-23 2016-03-22 Химерный антигенный рецептор RU2752880C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1504840.8A GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor
GB1504840.8 2015-03-23
PCT/GB2016/050795 WO2016151315A1 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor

Publications (3)

Publication Number Publication Date
RU2017132978A RU2017132978A (ru) 2019-04-08
RU2017132978A3 RU2017132978A3 (cg-RX-API-DMAC7.html) 2019-06-24
RU2752880C2 true RU2752880C2 (ru) 2021-08-11

Family

ID=53052211

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017132978A RU2752880C2 (ru) 2015-03-23 2016-03-22 Химерный антигенный рецептор

Country Status (21)

Country Link
US (1) US11058722B2 (cg-RX-API-DMAC7.html)
EP (1) EP3274366B8 (cg-RX-API-DMAC7.html)
JP (3) JP6675417B2 (cg-RX-API-DMAC7.html)
KR (1) KR102174280B1 (cg-RX-API-DMAC7.html)
CN (1) CN107406518B (cg-RX-API-DMAC7.html)
AU (1) AU2016238583B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018252A2 (cg-RX-API-DMAC7.html)
CA (1) CA2978852C (cg-RX-API-DMAC7.html)
CL (1) CL2017002413A1 (cg-RX-API-DMAC7.html)
DK (1) DK3274366T3 (cg-RX-API-DMAC7.html)
ES (1) ES2773527T3 (cg-RX-API-DMAC7.html)
GB (1) GB201504840D0 (cg-RX-API-DMAC7.html)
HU (1) HUE047929T2 (cg-RX-API-DMAC7.html)
IL (1) IL254254B (cg-RX-API-DMAC7.html)
MX (1) MX371384B (cg-RX-API-DMAC7.html)
PL (1) PL3274366T3 (cg-RX-API-DMAC7.html)
PT (1) PT3274366T (cg-RX-API-DMAC7.html)
RU (1) RU2752880C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201706940QA (cg-RX-API-DMAC7.html)
WO (1) WO2016151315A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201705682B (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
US20200181225A1 (en) * 2017-03-29 2020-06-11 Sunnybrook Research Institute Engineered t-cell modulating molecules and methods of using same
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
CN111295392A (zh) 2017-11-01 2020-06-16 豪夫迈·罗氏有限公司 Compbody–多价靶结合物
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
WO2019220109A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
CN112930186A (zh) * 2018-08-16 2021-06-08 纪念斯隆-凯特琳癌症中心 基于亮氨酸拉链的组合物和使用方法
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
SG11202102781UA (en) 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
KR20210072797A (ko) * 2018-10-05 2021-06-17 세인트 안나 킨더크렙스포르슝 키메라 항원 수용체(car) 그룹
JP2022512594A (ja) * 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体(car)の群
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210132668A (ko) * 2019-02-21 2021-11-04 아르벨 리미티드 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
CA3138633A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
AU2020382219A1 (en) 2019-11-13 2022-05-12 Crispr Therapeutics Ag Manufacturing process for making T cells expressing chimeric antigen receptors
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202017649D0 (en) 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) * 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2024019961A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cd2 recruiting chimeric antigen receptors and fusion proteins
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2026151982A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127261A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
KR101156085B1 (ko) * 2010-01-29 2012-06-20 국립암센터 4-1bb리간드(4-1bbl)오중합체 및 이의 용도
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
JP6053688B2 (ja) * 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
CN103145849B (zh) 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
NZ759969A (en) * 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127261A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
AHMAD E. et al. Revisiting ligand-induced conformational changes in proteins: essence, advancements, implications and future challenges, Journal of Biomolecular Structure and Dynamics, 2013, V. 31, N. 6, p.630-648. *
BRIDGEMAN J. S. et al. The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex, The Journal of Immunology, 2010, V. 184, N. 12 p.6938-6949. *
BURNS W. R. et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas, Cancer research, 2010, V. 70, N. 8, p.3027-3033. *
CHANG H. C. et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments, Proceedings of the National Academy of Sciences, 1994, V. 91, N. 24, p.11408-11412. *
CHEN X. et al. Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, V. 65, N. 10, p.1357-1369. *
CORDOBA S. P. et al. The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor, Blood, The Journal of the American Society of Hematology, 2013, V. 121, N. 21, p.4295-4302. *
DODGE G. R. et al. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts, Osteoarthritis and Cartilage, 1998, V. 6, N. 6, p.435-440. *
DOLEZAL O. et al. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers, Protein engineering, 2000, V. 13, N. 8, p.565-574. *
GUEST R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens, Journal of immunotherapy, 2005, V. 28, N. 3, p.203-211. *
GUEST R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens, Journal of immunotherapy, 2005, V. 28, N. 3, p.203-211. CHANG H. C. et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments, Proceedings of the National Academy of Sciences, 1994, V. 91, N. 24, p.11408-11412. DODGE G. R. et al. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts, Osteoarthritis and Cartilage, 1998, V. 6, N. 6, p.435-440. HOLDEN P. et al. Secretion of cartilage oligomeric matrix protein is affected by the signal peptide, Journal of Biological Chemistry, 2005, V. 280, N. 17, p.17172-17179. AHMAD E. et al. Revisiting ligand-induced conformational changes in proteins: essence, advancements, implications and future challenges, Journal of Biomolecular S *
HOLDEN P. et al. Secretion of cartilage oligomeric matrix protein is affected by the signal peptide, Journal of Biological Chemistry, 2005, V. 280, N. 17, p.17172-17179. *
IRVING B. A. et al. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways, Cell, 1991, V. 64, N. 5, p.891-901. *
MAEDA Y. et al. Engineering of functional chimeric protein G-VargulaLuciferase, Analytical biochemistry, 1997, V. 249, N. 2, p.147-152. *
MAUS M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer immunology research, 2013, V. 1, N. 1, p.26-31. *
TEPLYAKOV A. et al. Antibody modeling assessment II. Structures and models, Proteins: Structure, Function, and Bioinformatics, 2014, V. 82, N. 8, p.1563-1582. *
ЛИКАРЬ Ю. Н. и др. Использование мутированного варианта человеческой деоксицитидинкиназы в качестве репортерного гена для оценки адоптивной Т-клеточной терапии, Вопросы гематологии, онкологии и иммунопатологии в педиатрии, 2012, V. 11, N. 2, с.23-31. *

Also Published As

Publication number Publication date
US20180050065A1 (en) 2018-02-22
MX371384B (es) 2020-01-28
IL254254A0 (en) 2017-10-31
HUE047929T2 (hu) 2020-05-28
RU2017132978A3 (cg-RX-API-DMAC7.html) 2019-06-24
ES2773527T3 (es) 2020-07-13
IL254254B (en) 2021-04-29
NZ735267A (en) 2021-04-30
CA2978852C (en) 2021-10-19
WO2016151315A1 (en) 2016-09-29
RU2017132978A (ru) 2019-04-08
EP3274366A1 (en) 2018-01-31
JP6675417B2 (ja) 2020-04-01
EP3274366B1 (en) 2019-12-11
US11058722B2 (en) 2021-07-13
BR112017018252A2 (pt) 2018-04-10
PL3274366T3 (pl) 2020-06-15
KR20180009738A (ko) 2018-01-29
EP3274366B8 (en) 2020-02-12
SG11201706940QA (en) 2017-09-28
CN107406518B (zh) 2022-02-01
AU2016238583A1 (en) 2017-09-28
CA2978852A1 (en) 2016-09-29
GB201504840D0 (en) 2015-05-06
AU2016238583B2 (en) 2020-08-13
JP2020048588A (ja) 2020-04-02
MX2017010552A (es) 2018-03-14
PT3274366T (pt) 2020-01-30
CL2017002413A1 (es) 2018-03-16
DK3274366T3 (da) 2020-02-10
ZA201705682B (en) 2018-12-19
JP2018510639A (ja) 2018-04-19
JP2023021396A (ja) 2023-02-10
KR102174280B1 (ko) 2020-11-04
CN107406518A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
JP6675417B2 (ja) キメラ抗原受容体
US11180553B2 (en) Chimeric antigen receptor
JP7395249B2 (ja) 細胞
US10604570B2 (en) Chimeric antigen receptor signalling system comprising heterodimerization domains
JP2018532407A (ja) 受容体
WO2017216562A1 (en) Tunable chimeric antigen receptors
KR20180002602A (ko) 레트로바이러스 및 렌티바이러스 벡터
BR112020007319A2 (pt) célula
WO2016174405A1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
US20240408134A1 (en) Cell
US20210030798A1 (en) Chimeric receptor
CN112996819B (zh) 细胞分选系统及使用方法
NZ735267B2 (en) Chimeric antigen receptor
HK1242346A1 (en) Chimeric antigen receptor
HK1242346B (en) Chimeric antigen receptor

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
PD4A Correction of name of patent owner